RBC Capital analyst Leonid Timashev initiated coverage of Revolution Medicines (RVMD) with an Outperform rating and $77 price target The firm believes Revolution is best positioned to execute on targeting RAS across oncology, given its “impressive” efficacy data, development lead, and pipeline. RBC thinks the company’s Phase III readout in 2026 is “highly likely to hit.”
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RVMD:
- Revolution Medicines: Promising Oncology Leader with Strategic Advancements and Competitive Edge
- Revolution Medicines Advances RAS(ON) Inhibitor Study in Gastrointestinal Cancers
- Revolution Medicines Advances RAS(ON) Inhibitors in NSCLC Study
- Revolution Medicines’ RASolve 301 Study: A Potential Game-Changer for NSCLC Treatment
- Revolution Medicines Advances Phase 3 Trial for Pancreatic Cancer Treatment